Examples of using Prolonged-release tablets in English and their translations into Hungarian
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Programming
-
Official/political
-
Computer
Viramune prolonged-release tablets have not been evaluated in patients with hepatic impairment
Patients already taking Oprymea tablets may be switched to Oprymea prolonged-release tablets overnight, at the same daily dose.
3.15 mg prolonged-release tablets are white to off-white and of oval shape.
Viramune prolonged-release tablets have not been studied in patients with hepatic impairment and Viramune immediate-release should be used.
tolerability of MIRAPEXIN prolonged-release tablets was detected.
Viramune prolonged-release tablets have not been studied in patients with renal dysfunction and Viramune immediate-release should be used.
tolerability of SIFROL prolonged-release tablets was detected.
Viramune prolonged-release tablets may be dosed based on a patient's weight
contents of the pack Circadin 2 mg prolonged-release tablets are available as white to off-white round bi-convex shaped tablets. .
Oprymea prolonged-release tablets should be taken within 12 hours after the regularly scheduled time.
Important information about some of the ingredients of Ranexa The 500 mg prolonged-release tablets contain the azo colouring agent E110, and the 750 mg prolonged-release tablets contain the azo colouring agent E102.
The side effects described below have been experienced by patients given Viramune prolonged-release tablets once daily in the maintenance phase.
Viramune 400 mg prolonged-release tablets are supplied in blisters, with 30 or 90 prolonged-release tablets per carton.
Viramune 50 mg prolonged-release tablets or 100 mg prolonged-release tablets should not be used by adults.
do not start taking Viramune prolonged-release tablets but consult your doctor.
Following steady-state administration of ropinirole prolonged-release tablets, the inter-individual variability for Cmax was between 30% and 55% and for AUC was between 40% and 70%.
Prolonged-release tablets are not suitable for the 14-day lead-in phase for patients starting nevirapine.
You should also take the prolonged-release tablets if the time to the regular next intake is shorter, but postpone the next intake by 8 hours.
The additional studies showed that the prolonged-release tablets were as effective as the immediate- release tablets in HIV-infected patients.
The additional studies showed that the prolonged-release tablets were as effective as the immediate- release tablets in treating Parkinson's disease.